A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD)

Protocol No
NEURO-ARIBIO-POLARIS-AD
Staff Member
Malgorzata Franczak
Phase
III
Summary

This project is being done to find out if an investigational new drug called AR1001 can help people with Alzheimer’s Disease and to see if the drug is safe.
Objective
AR1001 in Participants With Early Alzheimer's Disease
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Alzheimer's and Dementia, Brain, Spinal Cord, and Nervous System
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05531526